Freeman Mason 4
4 · CinCor Pharma, Inc. · Filed Jan 30, 2023
Insider Transaction Report
Form 4
Freeman Mason
EVP Clinical Development
Transactions
- Award
Common Stock
2023-01-26+40,000→ 42,500 total
Holdings
- 100(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.
- [F2]The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein.